Market
Scenario
The
global dyspepsia market is expected to witness a positive growth during the
forecast period. Dyspepsia is a chronic medical condition, that causes
discomfort in the upper abdomen of the patient due to indigestion. The
gastrointestinal organs, the stomach and the small intestine (sometimes the
esophagus), do not function normally. Gastrointestinal causes of dyspepsia are
gastritis, peptic ulcers, gallstones, stomach cancer, constipation, reduced
blood flow in the intestine (intestinal ischemia). Nongastrointestinal causes
are diabetes, thyroid disease, kidney disease and consumption of drugs like
nonsteroidal anti-inflammatory drugs (NSAIDs such as ibuprofen),
antibiotics and others. Dyspepsia is also caused due to overeating, smoking and
extreme consumption of alcohol. Increasing prevalence of digestive diseases is
the key factor for the market to grow. According to the Centers for Disease
Control and Prevention in 2016, 14.7 million people in the US suffered from
digestive ulcers. Such a high prevalence of digestive diseases enhances the
market growth during the forecast period. Other factors like growing caffeine
intake, increasing alcohol consumption, rising prevalence of diabetes,
increasing incidences of thyroid diseases and stomach cancer, robust R&D
activities to develop new drugs and advancement in diagnosis and treatment
technologies is driving the growth of the market.
However,
factors such as expensive diagnosis test and intense competition among the
major market players to gain maximum market share are expected to restrict the
market growth during the forecast period.
Segmentation
The
global dyspepsia market is segmented on the basis of diagnosis, treatment, and
end-user. The dyspepsia market, by diagnosis, is sub-segmented into blood
tests, breath tests, stool tests, endoscopy, X-ray, CT scan, and others. On the
basis of treatment, the market is categorized into antacids, antibiotics, h2
blockers, proton pump inhibitors (PPIs), prokinetics, psychological therapies
and others. Antacids are further sub-segmented into calcium carbonate,
loperamide, simethicone, sodium bicarbonate and others. Antibiotics further
sub-segmented into amoxicillin, clarithromycin, metronidazole, and
others. H2 blockers are further categorized into cimetidine, famotidine,
nizatidine, ranitidine, and others. Proton pump inhibitors (PPIs) is
further segmented into esomeprazole, lansoprazole, and omeprazole. Prokinetics
are categorized into bethanechol and metoclopramide. On the basis of end-user,
the market is segmented into hospitals and clinics, ambulatory surgical
centers, pharmacies, diagnostic centers and others.
On the
basis of region, the global dyspepsia market is segmented into the Americas,
Europe, Asia-Pacific, and the Middle East and Africa. The Americas is
sub-segmented into North America and South America. The North American region
is further segmented into the U.S. and Canada. The European region is divided
into two, namely, Western Europe and Eastern Europe. Western Europe is further
classified into Germany, Italy, France, the U.K., Spain, and the rest of
Western Europe. The Asia-Pacific region is sub-segmented into Japan, China,
India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The
Middle Eastern and African region is sub-segmented into the United Arab
Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East
and Africa.
Key
players
Some of
the key players for the global dyspepsia market are AstraZeneca,
GlaxoSmithKline, Takeda Pharmaceutical Company, Johnson & Johnson, Eisai
Co., Ltd., Abbott Laboratories, Salix Pharmaceuticals, Bayer AG, Boehringer
Ingelheim GmbH, Sanofi, Allergan Plc, and others.
Regional Analysis
The
dyspepsia market is dominated by North America owing to rising prevalence of
ulcerative colitis.
Ulcerative
Colitis causes inflammation of the digestive tract which may lead to
dyspepsia. According to the Centers for Disease Control and Prevention in 2015,
3 million people suffered from ulcerative colitis. Also, the increased adoption
of technologically advanced devices and the high amount of healthcare
expenditure drives the market growth in this region.
It is
estimated that Europe stood second in the global dyspepsia market. Thus,
increasing prevalence of chronic digestive disease in Europe contributes to
market growth. According to the United European Gastroenterology report
published in 2018, 365,000 deaths in Europe were due to digestive cancers.
Also, rising healthcare expenditure and R&D activities are driving the
growth of this market in Europe.
Asia-Pacific
was projected to be the fastest growing region for the global dyspepsia market.
Key factors such as rising number of patient population, increase in the
adoption of minimally invasive surgeries, and rapid rise in endoscopy for the
diagnosis and treatment of digestive diseases, influences the market in this
region. Also, the rising medical tourism in countries like Malaysia, India, and
Thailand drives market growth in this region.
The
Middle East and Africa holds the least share of the global dyspepsia market due
to the presence of stringent government policies and poor economies. However,
increasing investment by private market players and growing government
initiatives in this region can boost the market growth.
TABLE OF CONTENT
Chapter 1. Report
Prologue
Chapter 2. Market
Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research
Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size
Estimation
Chapter 4. Market
Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic
Indicators
4.6 Technology Trends
& Assessment
Chapter 5. Market Factor
Analysis
5.1 Porters Five Forces
Analysis
5.1.1 Bargaining Power Of
Suppliers
5.1.2 Bargaining Power Of
Buyers
5.1.3 Threat Of New
Entrants
5.1.4 Threat Of
Substitutes
5.1.5 Intensity Of
Rivalry
About
US:
Market
Research Future (MRFR), enable customers to unravel the complexity of various
industries through Cooked Research Report (CRR), Half-Cooked Research Reports
(HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market
Research & Consulting Services.
Contact
Us:
Market
Research Future
Office
No. 528, Amanora Chambers
Magarpatta
Road, Hadapsar,
Pune
- 411028
Maharashtra,
India
Phone:
+1 646 845 9312
Email:
sales@marketresearchfuture.com
